3 recruiting, 1 active not recruiting, 1 terminated, 1 withdrawn. 4 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Recruiting 3, Active not recruiting 1 |
| Phase 1 | 3 | Recruiting 1, Terminated 1, Withdrawn 1 |
Follow QuantumLeap Healthcare Collaborative: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment Tamoxifen, Exemestane, Letrozole - Ductal Carcinoma in Situ | Phase 2 | Recruiting | QuantumLeap Healthcare Collaborative | 400 | 2024-02-17 | 2026-09-28 |
| PRE-ISPY Phase I/II Oncology Platform Program ALX148, Fam-Trastuzumab Deruxtecan-Nxki, Zanidatamab - HER2-positive Breast Cancer, Metastatic Cancer | Phase 1 / Phase 2 | Recruiting | QuantumLeap Healthcare Collaborative | 280 | 2023-02-15 | 2026-09-30 |
| ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer Vic-trastuzumab duocarmazine (SYD985) + paclitaxel - HER2-positive Breast Cancer, HER2 Low | Phase 1 | Withdrawn | QuantumLeap Healthcare Collaborative | 2021-07-28 | 2023-11-18 | |
| I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients Remdesivir, Imatinib Mesylate, Dexamethasone - COVID-19 | Phase 2 | Active not recruiting | QuantumLeap Healthcare Collaborative | 1500 | 2020-07-31 | 2026-03-16 |
| Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer BMN-673, Carboplatin, Paclitaxel - Triple Negative Metastatic Breast Cancer, BRCA-mutated Solid Tumor | Phase 1 | Terminated | Pamela Munster | 23 | 2015-02-23 | 2020-01-10 |
| I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer Standard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin - Breast Neoplasms, Breast Cancer | Phase 2 | Recruiting | QuantumLeap Healthcare Collaborative | 5000 | 2010-03-01 | 2026-05-06 |
Breast Neoplasms (3) · Triple Negative Breast Neoplasms (3) · Neoplasm Metastasis (2) · Adenocarcinoma (1) · COVID-19 (1) · Carcinoma, Intraductal, Noninfiltrating (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Disease (1) · Endometrial Neoplasms (1) · Hemangiosarcoma (1) · Neoplasm, Residual (1) · Neoplasms (1) · Ovarian Neoplasms (1) · Pathologic Complete Response (1)
Paclitaxel (3) · 4-hydroxy-N-desmethyltamoxifen (2) · Carboplatin (2) · Letrozole (2) · talazoparib (2) · trastuzumab duocarmazine (2) · tucatinib (2) · zanidatamab (2) · ALX148 (1) · ARX788 (1) · Ado-Trastuzumab Emtansine (1) · Anastrozole (1) · Celecoxib (1) · Cyclosporine (1) · Cyproheptadine (1)
United States (6)
Laura Esserman, MD, MBA (2) · Paula R Pohlmann, MD, MSc, PhD (2) · Anthony Elias, MD (1) · Derek W Russell, MD (1) · Kathleen D Liu, MD (1) · Laura Esserman, MD (1) · Pamela Munster, MD (1)
PMID 21796368, PMID 22198468, PMID 22623692, PMID 22649152, PMID 27406346, PMID 27406347, PMID 28851423, PMID 32031889, PMID 32053137, PMID 32450725, PMID 32701140, PMID 34473343, PMID 34529000, PMID 34741021, PMID 35623341, PMID 35993306, PMID 36069821, PMID 36456573, PMID 36883141, PMID 37029329, PMID 37325931, PMID 37505107, PMID 38086377, PMID 38180338, PMID 38745646, PMID 39158353, PMID 39277671, PMID 39277672, PMID 39592213, PMID 39613746, PMID 39625569, PMID 40462830, PMID 40526879, PMID 40551254, PMID 40639409, PMID 40679371, PMID 40777112, PMID 41879562, PMID 42530945, PMID 42545411, PMID 42619946, PMID 42799508, PMID 42811224